Organovo (NASDAQ:ONVO) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Organovo (NASDAQ:ONVO) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the medical research company’s stock.

Organovo Stock Performance

NASDAQ:ONVO opened at $0.36 on Thursday. The firm’s 50-day moving average is $0.40 and its 200-day moving average is $0.47. The company has a market cap of $5.56 million, a price-to-earnings ratio of -0.34 and a beta of 0.56. Organovo has a 52-week low of $0.32 and a 52-week high of $1.74.

Organovo (NASDAQ:ONVO) last issued its quarterly earnings results on Friday, November 8th. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.12. Organovo had a negative return on equity of 249.28% and a negative net margin of 12,176.70%. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.04 million. Equities analysts predict that Organovo will post -0.77 EPS for the current year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.